National Spotlight on FDA and Duchenne Muscular Dystrophy: What This Means for Everyone with a Rare Disease
Written by Jennifer Huron on November 20, 2015
Next week, a Food and Drug Administration panel of experts will hold the first of two meetings to review two drugs designed to slow the muscle wasting effects associated with Duchenne Muscular Dystrophy (DMD). These much-anticipated events provide hope for… Read More
